Paediatric European Network for Treatment of AIDS (PENTA). Five year follow up of vertically infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child 2001; 84: 230–236.
et al. Disease progression in HIV infected infants and children: predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count. JAMA 1998; 279: 756–761.
et al. The relationship between human immunodeficiency type 1 RNA level, CD4 lymphocyte percent, and mortality risk in HIV-1 infected children. J Infect Dis 1997; 175: 1029–1038.
HIV Pediatric Prognostic Markers Collaborative Study Group. Short term risk of disease progression in HIV-1 infected children receiving no antiretroviral therapy or zidovudine monotherapy; a meta-analysis. Lancet 2003; 362: 1605–1611.
et al. Decline in mortality, AIDS and hospital admissions in perinatally HIV-1 infected children in the UK and Ireland. BMJ 2003; 327: 1019–1021.
II Conference of International AIDS Society, Paris, 2003 [Abstract 33]. Mortality and morbidity in HIV-infected infants treated before 6 months of age.
et al. Early HAART in infants: a multicenter Spanish audit. 9th European AIDS Conference (EACS), Warsaw, 2003 [Abstract 15.2/2]., ,
et al. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J 2002; 21: 518–525.
Pediatric European Network for treatment of AIDS. A 72 week follow-up of HAART started in infants aged less than 3 months: CD4, viral load and drug resistance in the PENTA7 study. AIDS 2004; 18: 237–245.
et al. Early therapy of vertical human immunodeficiency virus type-1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1 specific immune responses. J Virol 2000; 74: 6984–6991.
Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection. Arch Dis Child 1997; 76: 334–336.
et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 19–129. , ,
et al. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003; 17: 1863–1869.
ATCC – The Antiviral Therapy Cohort Collaboration. Prognostic importance of initial response in HIV-infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362: 679–686.
et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 2003; 22: 48–55.
et al. Baby cocktail! A protease-sparing 4 drug combination for symptomatic children. XIV International AIDS Conference, Barcelona, 2002 [Abstract MoOrB1129]., ,
et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy experienced HIV infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 2000; 283: 492–498.
et al. Combination nucleoside analog reverse transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral experienced HIV infected children: week 24 of a randomised controlled trial – PACTG 377. AIDS Res Human Retro 2000; 16: 1113–1121.
et al. for the PENTA 5 Steering Committee. Three-year follow-up of the PENTA 5 Trial. 10th Conference of Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 874]., ,
PENTA. Comparison of dual nucleoside analogue reverse-transcriptase inhibitor regimens with and without NFV in children with HIV who have not previously been treated: the PENTA 5 trial. Lancet 2002; 359: 733–740.
2nd International AIDS Society Conference, Paris, 2003 [Abstract 548].. Nelfinavir 625 mg film-coated tablets. Investigation of safety and gastrointestinal tolerability of this new formulation in comparison with 250 mg film-coated tablets in HIV patients.
et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus infected children. Pediatr Infect Dis J 2003; 22: 216–223.
et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865–1873.
et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse transcriptase inhibitors in children infected with human immunodeficiency virus type 1. New Engl J Med 1999; 341: 1874–1881.
et al. for the ACTG 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New Engl J Med 2003; 349: 2293–2303.
et al. Nevirapine use in HIV-1 infected children. AIDS 2003; 17: 1639–1647.
et al. Tolerance of efavirenz in children. AIDS 2001; 15: 241–243.
Vibhagool A on behalf of the CNA3014 International Study Team. Ziagen (abacavir)/combivir versus indinavir/combivir in therapy naïve adults. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
et al. Efficacy and safety of a quadruple combination combivir+abacavir+efavirenz regimen in antiretrovial treatment naive HIV-1 infected adults: La ranciliene. J Acquir Immune Defic Syndr 2002; 31: 178–182. , ,
World Aids Conference, Bangok, 2004 [Abstract 2038]., , . Triple nucleoside analogue therapy with zidovudine (AZT) lamivudine (3TC) and abacavir (ABC) in the paediatric HIV in South London (PHILS-NET) cohort. A 72 week update.
et al. Pharmacokinetics of once daily vs. twice daily lamivudine and abacavir in HIV-1 infected children: PENTA 13. 11th Conference on Retroviruses and Opportunistic Infections, S. Francisco, 2004 [Abstract 934]., ,
et al. Pharmacokinetics and safety of single oral doses emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004; 48: 183–190.
et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004; 48: 124–129.
et al. Safety, tolerability and clinical responses to tenofovir DF in combination with other antiretrovirals in heavily treatment-experienced HIV-infected children: data through 48 weeks. 11th Conference on Retroviruses and Opportunistic Infections, S. Francisco, 2004 [Abstract 928]., ,
et al. PACTG 1021: an ongoing phase I/II study of once-daily emtricabine, didanosine, and efavirenz in therapy-naive or minimally treated pediatric patients. 10°Conference of Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 873]., ,
et al. for FTC-203 Study Team. Once-daily emtricitabine in HIV-infected pediatric patients with other antiretroviral agents. 10th Conference of Retrovirus and Opportunistic Infection, Boston, 2003 [Abstract 872]., ,
et al. A virological benefit from an induction/maintenance strategy: The FORTE Trial. 11th Conference on Retroviruses and Opportunistic Infections, Chicago, 2004 [Abstract 564]., ,
Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the first pediatric switch study. Pediatrics 2003; 3: 275–281. , , , ,
et al. IMMUNOLOGIC CHANGES DURING UNPLANNED TREATMENT interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2000; 63: 446–450.
Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003; 63: 741–753.
, , , ,
et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349: 837–846.
et al. Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children. AIDS 2003; 17: 2181–2189.
et al. Reported adherence as a determinant of response to HAART in children who have HIV infection. Pediatrics 2002; 109: e61.
Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 1763–1769.
, , ,
et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21–30.
Assessment of adherence to antiviral therapy in HIV-infected children using the medication Event monitoring system, pharmacy refill, provider assessment, Caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr 2003; 33: 211–218. ,
Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999; 18: 682–689.
et al. Adherence to medication regimens among human immunodeficiency virus infection. Pediatr Infect Dis J 2000; 19: 1148–1153.
for the PENTA Steering Committee. Adherence to prescribed antiretroviral therapy in with human immunodeficiency virus infected children. Pediatr Infect Dis J 2003; 22: 56–62.
, , , , ,
Assessment of adherence in human immunodeficiency virus infected children. Pediatr Infect Dis J 2001; 20: 1174–1176.
, , ,
Gastrostomy tube placement in nonadherent HIV-infected children. Ann Pharmacother 2001; 35: 414–418.
Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children. Arch Pediatr Adolesc Med 2002; 156: 568–573.
, , , ,
Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003; 22: 77–84.
Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 405–410.
, , , ,
et al. High prevalence of metabolic abnormalities in HIV-infected children treated with HAART. 10th Conference on Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 772]., ,
et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14: 2123–2128.
10th Conference on Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 774]., . Fat redistribution and metabolic abnormalities in HIV-infected children and adolescents in Europe.
Lypodystrophy in HIV-infected children is associated with high viral load and low CD4-lymphocyte count and CD4-lymphocyte percentage and baseline and use of protease inhibitors and stavudine. J Acquir Immun Def Syndr 2001; 27: 30–34.
, , , ,
et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001; 15: 2415–2422.
6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 [Abstract 435]., . Hypercholesterolemia in children treated with HIV protease inhibitors.
et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr J 2002; 30: 288–293.
et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002; 31: 257–275.
Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 2000; 31: 167–169.
et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis J 2003; 22: 778–782.
et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 2001; 138: 748–751.
Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22: 782–789.
, , , ,
et al. Persistent mitochondrial dysfunction and perinatal exposure to antirtroviral nucleoside analogues. Lancet 1999; 354: 1084–1089.
et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17: 1769–1785.
et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137: 17–24.
for the PACTG 219 Team. Avascular necrosis of the hip (Leggs-Calve-Perthes disease) in HIV-infected children in long-term follow-up: PACTG Study 219. Pediatrics 2002; 109: e74, 1–8. , , , ,
et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14: F63–F67.
HIV infection – a risk factor for osteoporosis. J Acquir Immune Def Syndr 2003; 33: 281–291.
Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Def Syndr 2002; 29: 450–454.
, , , , ,
11th Conference on Retrovirus and Opportunistic Infections, S. Francisco, 2004 [Abstract 943]., , , , , . Analysis of bone mineral content in antiretroviral-naive and highly active antiretroviral treated HIV-infected children.
et al. Effect of HAART on bone density in HIV-infected children. 10th Conference on Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 778]., ,
14th World AIDS Conference, Barcelona, 2002 [Abstract TuPpB 2053]., , , , , . Bone disorders in HIV-infected and -exposed children.
et al. Alendronate, vitamin D and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. 10th Conference on Retrovirus and Opportunistic Infections, Boston, 2003 [Abstract 134]., ,
et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 298–302.